BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/29/2021 9:44:51 AM | Browse: 430 | Download: 695
 |
Received |
|
2021-02-19 22:35 |
|
Peer-Review Started |
|
2021-02-19 22:42 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-07-30 00:55 |
|
Revised |
|
2021-08-08 21:41 |
|
Second Decision |
|
2021-12-14 03:39 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-12-23 06:30 |
|
Articles in Press |
|
2021-12-23 06:30 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-12-27 07:00 |
|
Publish the Manuscript Online |
|
2021-12-29 09:44 |
| ISSN |
2220-315x (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pathology |
| Manuscript Type |
Minireviews |
| Article Title |
Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: A comprehensive review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Hua Li, Zhi-Yan Fu, Mustafa Erdem Arslan, Daniel Cho and Hwajeong Lee |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hwajeong Lee, MD, Associate Professor, Department of Pathology and Laboratory Medicine, Albany Medical Center, 47 New Scotland Ave. MC81, Albany, NY 12208, United States. leeh5@amc.edu |
| Key Words |
Immune checkpoint inhibitor; Immune checkpoint inhibitor-induced colitis; Infliximab; Vedolizumab; Graft-versus-host disease; Inflammatory bowel disease |
| Core Tip |
Colitis is the most common adverse effect associated with immune checkpoint inhibitor (ICI) therapy. Its clinical, endoscopic and histopathologic presentations overlap with those of colitis caused by other etiologies, including infection, other medications and graft-versus-host disease. Patients often present with diarrhea, abdominal pain and variable endoscopic findings ranging from normal or mild inflammation to ulcerations. Microscopically, acute colitis pattern of injury is the most common finding. ICI-induced colitis is a diagnosis of exclusion. Its current first-line treatment is corticosteroids, followed by infliximab for steroid-refractory colitis. Vedolizumab and fecal microbiota transplantation are promising options for treatment-refractory ICI-induced colitis. |
| Publish Date |
2021-12-29 09:44 |
| Citation |
Li H, Fu ZY, Arslan ME, Cho D, Lee H. Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: A comprehensive review. World J Exp Med 2021; 11(6): 79-92 |
| URL |
URL:https://www.wjgnet.com/2220-315x/full/v11/i6/79.htm |
| DOI |
https://dx.doi.org/10.5493/wjem.v11.i6.79 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
